Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 18/20 | 0.65 |
| ▸ | PPARG | P37231 | 3/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.43 |
| ▸ | ADH5 | P11766 | 1/20 | 0.41 |
| ▸ | RARG | P13631 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17912658 | 0.84 | RORC (0.48) | RORCPPARGCYP2C9RARG | |
| SCHEMBL17912628 | 0.81 | RORC (0.63) | RORCPPARGCYP2C9RARG | |
| SCHEMBL17912526 | 0.80 | RORC (0.52) | RORCPPARGADH5RARG | |
| SCHEMBL17912710 | 0.80 | RORC (0.52) | RORCPPARGADH5RARG | |
| SCHEMBL17912592 | 0.79 | RORC (0.55) | RORCPPARGCYP2C9ADH5RARG | |
| SCHEMBL16582383 | 0.79 | RORC (1.00) | RORCPPARGCYP2C9RARG | |
| SCHEMBL17912684 | 0.78 | RORC (0.48) | RORCPPARGCYP2C9ADH5RARG | |
| SCHEMBL17912629 | 0.77 | RORC (0.50) | RORCPPARGCYP2C9 | |
| SCHEMBL17912735 | 0.75 | RORC (0.53) | RORCPPARGCYP2C9 | |
| SCHEMBL17912589 | 0.74 | RORC (0.47) | RORCPPARGCYP2C9ADH5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3242878-B1 | BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD (IN) | 2020-10-14 | — | — | EP | claimed |
| US-20170362225-A1 | BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2017-12-21 | — | — | US | claimed |
| EP-3242878-A1 | BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | Advinus Therapeutics Limited (IN) | 2017-11-15 | — | — | EP | claimed |
| WO-2016110821-A1 | BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2016-07-14 | — | — | WO | claimed |
| EP-3242878-B1 | BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD (IN) | 2020-10-14 | — | — | EP | disclosed |
| US-10435402-B2 | Bicyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2019-10-08 | — | — | US | disclosed |
| US-20170362225-A1 | BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2017-12-21 | — | — | US | disclosed |
| EP-3242878-A1 | BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | Advinus Therapeutics Limited (IN) | 2017-11-15 | — | — | EP | disclosed |
| WO-2016110821-A1 | BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2016-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362225-A1 | BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | RORC, RORA, RORB | RORC 1/4885PPARG 31/4885CYP2C9 298/4885 |
| US-10435402-B2 | Bicyclic compounds, compositions and medicinal applications thereof | RORA, RORB, RORC | RORC 3/4885PPARG 53/4885CYP2C9 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.